Chemotherapy regimen

Last updated

A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology, many regimens combine several chemotherapy drugs in combination chemotherapy. The majority of drugs used in cancer chemotherapy are cytostatic, many via cytotoxicity.

Contents

A fundamental philosophy of medical oncology, including combination chemotherapy, is that different drugs work through different mechanisms, and that the results of using multiple drugs will be synergistic to some extent. Because they have different dose-limiting adverse effects, they can be given together at full doses in chemotherapy regimens. [1]

The first successful combination chemotherapy was MOPP, introduced in 1963 for lymphomas.

The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow. [2]

Nomenclature

Chemotherapy regimens are often identified by acronyms, identifying the agents used in the drug combination. However, the letters used are not consistent across regimens, and in some cases - for example, "BEACOPP" - the same letter combination is used to represent two different treatments. [3]

There is no widely accepted naming convention or standard for the nomenclature of chemotherapy regimens. For example, either generic or brand names may be used for acronyms. This page merely lists commonly used conventions.

List of chemotherapy regimen acronyms

NameComponentsExample of uses, and other notes
7+3, also known as DA or DAC in case of daunorubicin, or IA or IAC in case of idarubicin use7 days of Ara-C (cytarabine) plus 3 days of an anthracycline antibiotic, either daunorubicin (DA or DAC variant) or idarubicin (IA or IAC variant) Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ABVD doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine Hodgkin's lymphoma
AC doxorubicin (Adriamycin), cyclophosphamide breast cancer
BACOD bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone Non-Hodgkin lymphomas
BEACOPP bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, prednisone Hodgkin's lymphoma
BEP bleomycin, etoposide, platinum agent testicular cancer, germ cell tumors
CA cyclophosphamide, doxorubicin (Adriamycin) (same as AC) breast cancer
CAF cyclophosphamide, doxorubicin (Adriamycin), fluorouracil (5-FU) breast cancer
CAPOX or XELOX capecitabine and oxaliplatin colorectal cancer
CAV cyclophosphamide, doxorubicin (Adriamycin), vincristine lung cancer
CBV cyclophosphamide, BCNU (carmustine), VP-16 (etoposide) lymphoma
CHOEP cyclophosphamide, hydroxydaunorubicin (doxorubicin), etoposide, vincristine (Oncovin), prednisone Non-Hodgkin lymphomas
CEPP cyclophosphamide, etoposide, procarbazine, prednisone Non-Hodgkin Lymphomas
ChlVPP/EVA chlorambucil, vincristine (Oncovin), procarbazine, prednisone, etoposide, vinblastine, doxorubicin (Adriamycin) Hodgkin's lymphoma
CHOP cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin), prednisone non-Hodgkin lymphoma
CHOP-R or R-CHOP CHOP + rituximab B cell non-Hodgkin lymphoma
ClaPD clarithromycin, pomalidomide, dexamethasone multiple myeloma
CMF cyclophosphamide, methotrexate, fluorouracil (5-FU) breast cancer
CMV cisplatin, methotrexate, vinblastine transitional bladder carcinoma
COP or CVP cyclophosphamide, Oncovin (vincristine), prednisone non-Hodgkin lymphoma in patients with history of cardiovascular disease
COPP cyclophosphamide, Oncovin (vincristine), procarbazine, prednisone Hodgkin's lymphoma
CT or TC docetaxel (Taxotere), cyclophosphamide breast cancer
CTD cyclophosphamide, thalidomide, dexamethasone AL amyloidosis
CVAD and Hyper-CVAD cyclophosphamide, vincristine, doxorubicin (Adriamycin), dexamethasone aggressive non-Hodgkin lymphoma, lymphoblastic lymphoma, some forms of leukemia
CVEcarboplatin, vincristine, etoposideretinoblastoma
CYBORD cyclophosphamide, bortezomib, dexamethasone multiple myeloma, AL amyloidosis
DA or DAC daunorubicin x 3 days plus ara-C (cytarabine) x 7 days, a variant of 7+3 regimen Acute myeloid leukemia, excluding acute promyelocytic leukemia
DAT daunorubicin, cytarabine (ara-C), tioguanine Acute myeloid leukemia
DCEP dexamethasone, cyclophosphamide, etoposide, platinum agent relapsed or refractory multiple myeloma
DHAP dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent Non-Hodgkin lymphomas
DHAP-R or R-DHAP dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab Non-Hodgkin lymphomas
DICE dexamethasone, ifosfamide, cisplatin, etoposide (VP-16)aggressive relapsed lymphomas, progressive neuroblastoma
DT-PACE dexamethasone, thalidomide, platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
EC epirubicin, cyclophosphamide breast cancer
ECF (MAGIC) epirubicin, cisplatin, fluorouracil (5-FU) gastric cancer and cancer of the esophagogastric junction (Siewert classification III)
EOX epirubicin, oxaliplatin, capecitabine esophageal Cancer, gastric Cancer
EP etoposide, platinum agent testicular cancer, germ cell tumors
EPOCH etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin Non-Hodgkin lymphomas
EPOCH-R or R-EPOCH etoposide, prednisone, vincristine (Oncovin), cyclophosphamide, and hydroxydaunorubicin plus rituximab B cell Non-Hodgkin lymphomas
ESHAP etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent Non-Hodgkin lymphoma
ESHAP-R or R-ESHAP etoposide, methylprednisolone (a steroid hormone), cytarabine (ara-C), platinum agent plus rituximab Non-Hodgkin lymphoma
FAM fluorouracil, doxorubicin (Adriamycin), mitomycin gastric cancer
FAMTX fluorouracil, doxorubicin (Adriamycin), methotrexate gastric cancer
FCM or FMC fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
FCM-R or R-FCM or R-FMC or FMC-R fludarabine, cyclophosphamide, mitoxantrone plus rituximab B cell non-Hodgkin lymphoma
FCR fludarabine, cyclophosphamide, rituximab B cell non-Hodgkin lymphoma
FM fludarabine, mitoxantrone B cell non-Hodgkin lymphoma
FM-R or R-FM or RFM or FMR fludarabine, mitoxantrone, and rituximab B cell non-Hodgkin lymphoma
FEC fluorouracil (5-FU), epirubicin, cyclophosphamide breast cancer
FEC-T fluorouracil (5-FU), epirubicin, cyclophosphamide together, followed by docetaxel (Taxotere) breast cancer
FL (also known as Mayo) fluorouracil (5-FU), leucovorin (folinic acid) colorectal cancer
FLAG fludarabine, cytarabine, G-CSF relapsed or refractory acute myelogenous leukemia
FLAG-Ida or FLAG-IDA or IDA-FLAG or Ida-FLAG fludarabine, cytarabine, idarubicin, G-CSF relapsed or refractory acute myelogenous leukemia
FLAG-Mito or FLAG-MITO or Mito-FLAG or MITO-FLAG or FLANG[ citation needed ] mitoxantrone, fludarabine, cytarabine, G-CSF relapsed or refractory acute myelogenous leukemia
FLAMSA fludarabine, cytarabine, amsacrine myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-BU or FLAMSA-Bu fludarabine, cytarabine, amsacrine, busulfan myelodysplastic syndrome, acute myeloid leukemia
FLAMSA-MEL or FLAMSA-Mel fludarabine, cytarabine, amsacrine, melphalan myelodysplastic syndrome, acute myeloid leukemia
FLOT fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, docetaxel esophageal cancer, gastric cancer
FOLFIRI fluorouracil (5-FU), leucovorin (folinic acid), irinotecan colorectal cancer
FOLFIRINOX fluorouracil (5-FU), leucovorin (folinic acid), irinotecan, oxaliplatin pancreatic cancer
FOLFOX fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin colorectal cancer
GC gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer
GDP gemcitabine, dexamethasone, cisplatin Non-Hodgkin lymphomas and Hodgkin lymphoma
GemOx or GEMOX gemcitabine, oxaliplatin Non-Hodgkin lymphomas
GVD gemcitabine, vinorelbine, pegylated liposomal doxorubicin Hodgkin lymphoma
GemOx-R or GEMOX-R or R-GemOx or R-GEMOX gemcitabine, oxaliplatin, rituximab Non-Hodgkin lymphomas
IA or IAC idarubicin x 3 days plus Ara-C (cytarabine) x 7 days, a variant of classical 7+3 regimen Acute myelogenous leukemia, excluding acute promyelocytic leukemia
ICE ifosfamide, carboplatin, etoposide (VP-16)aggressive lymphomas, progressive neuroblastoma
ICE-R or R-ICE or RICE ICE + rituximab high-risk progressive or recurrent lymphomas
IFL irinotecan, leucovorin (folinic acid), fluorouracil colorectal cancer
IVA ifosfamide, vincristine, actinomycin D rhabdomyosarcoma
MAP or MAPIE Doxorubicin (Adriamycin), Cisplatin, Methotrexate, Ifosfamide (Ifex), Etoposide (Vepesid) Bone cancer, Osteosarcoma
m-BACOD methotrexate, bleomycin, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone non-Hodgkin lymphoma
MACOP-B methotrexate, leucovorin (folinic acid), doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), prednisone, bleomycin non-Hodgkin lymphoma
MAID mesna, doxorubicin, ifosfamide, dacarbazine soft-tissue sarcoma
MINE mesna, ifosfamide, novantrone, etoposide Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MINE-R or R-MINE mesna, ifosfamide, novantrone, etoposide plus rituximab Non-Hodgkin lymphomas and Hodgkin lymphoma in relapse or refractory cases
MMM mitomycin, methotrexate, mitoxantrone breast cancer
MOPP mechlorethamine, vincristine (Oncovin), procarbazine, prednisone Hodgkin's lymphoma
MVAC methotrexate, vinblastine, doxorubicin (Adriamycin), cisplatin advanced bladder cancer [4]
MVP mitomycin, vindesine, cisplatin lung cancer and mesothelioma
NP cisplatin, vinorelbine non-small cell lung carcinoma
PACE platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide
PCV Procarbazine, CCNU (lomustine), vincristine brain tumors
PEB cisplatin, etoposide, bleomycin non-seminomatous germ cell tumors
PEI cisplatin, etoposide, ifosfamide small-cell lung carcinoma
platin + taxane [5] cisplatin/carboplatin, paclitaxel/docetaxel ovarian cancer
POMP6-mercaptopurine (Purinethol), vincristine (Oncovin), methotrexate, and prednisone acute adult leukemia [6]
ProMACE-MOPP methotrexate, doxorubicin (Adriamycin), cyclophosphamide, etoposide + MOPP non-Hodgkin lymphoma
ProMACE-CytaBOM prednisone, doxorubicin (Adriamycin), cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine (Oncovin), methotrexate, leucovorin non-Hodgkin lymphoma
RdC lenalidomide (Revlimid), dexamethasone, cyclophosphamide AL amyloidosis
R-Benda rituximab + bendamustine follicular lymphoma and MALT lymphoma [7]
R-DHAP or DHAP-R rituximab + DHAP; that is, rituximab, dexamethasone (a steroid hormone), cytarabine (ara-C), platinum agent relapsed non-Hodgkin's lymphoma and Hodgkin's lymphoma
R-FCM or FCM-R rituximab + FCM; that is, rituximab, fludarabine, cyclophosphamide, mitoxantrone B cell non-Hodgkin lymphoma
R-ICE or ICE-R or RICE rituximab + ICE; that is, rituximab, ifosfamide, carboplatin, etoposide high-risk progressive or recurrent lymphomas
RVD lenalidomide (Revlimid), bortezomib, dexamethasone
Stanford V doxorubicin (Adriamycin), mechlorethamine, bleomycin, vinblastine, vincristine, etoposide, prednisone Hodgkin lymphoma
TAC or ACT docetaxel (Taxotere) or paclitaxel (Taxol), doxorubicin (Adriamycin), cyclophosphamide breast cancer ("TAC" can also refer to tetracaine-adrenaline-cocaine, used as local anesthetic)
TAD tioguanine, cytarabine (ara-C), daunorubicin acute myeloid leukemia
TC or CT docetaxel (Taxotere), cyclophosphamide breast cancer
TCH docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin) breast cancer with positive HER2/neu receptor
TCHP docetaxel (Taxotere), carboplatin, trastuzumab (Herceptin), pertuzumab (Perjeta) breast cancer with positive HER2/neu receptor
Thal/Dex thalidomide, dexamethasone multiple myeloma
TIP paclitaxel (Taxol), ifosfamide, platinum agent cisplatin (Platinol) testicular cancer, germ cell tumors in salvage therapy
EE-4A vincristine, actinomycin [8] Wilms' tumor [8]
DD-4A vincristine, actinomycin, doxorubicin (Adriamycin) [8] Wilms' tumor [8]
VABCD vinblastine, doxorubicin (Adriamycin), bleomycin, lomustine (CeeNU), dacarbazine MOPP refractory Hodgkin's Lymphoma
VAC vincristine, actinomycin, cyclophosphamide rhabdomyosarcoma
VAD vincristine, doxorubicin (Adriamycin), dexamethasone multiple myeloma
VAMP one of 3 combinations of vincristine and others Hodgkin's lymphoma, leukemia, multiple myeloma
Regimen I vincristine, doxorubicin (Adriamycin), etoposide, cyclophosphamide Wilms' tumor [8]
VAPEC-B vincristine, doxorubicin (Adriamycin), prednisone, etoposide, cyclophosphamide, bleomycin Hodgkin's lymphoma
VDC-IE vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide Ewing's sarcoma
VD-PACE bortezomib, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
VIFUP vinorelbine, cisplatin, fluorouracil locally advanced/metastatic breast cancer
VIP vinblastine, ifosfamide, platinum agent, (etoposide (VP-16) may substitute for vinblastine, making a regimen sometimes referred to as VIP-16) [9] [10] testicular cancer, germ cell tumors
VTD-PACE bortezomib (Velcade), thalidomide, dexamethasone plus platinum agent, doxorubicin (Adriamycin), cyclophosphamide, etoposide multiple myeloma
V-DCEP bortezomib (Velcade), dexamethasone, cyclophosphamide, etoposide, platinum agent relapsed or refractory multiple myeloma

See also

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is the type of cancer treatment that uses one or more anti-cancer drugs in a standard regimen. Chemotherapy may be given with a curative intent, or it may aim only to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Anaplastic large-cell lymphoma</span> Medical condition

Anaplastic large-cell lymphoma (ALCL) refers to a group of non-Hodgkin lymphomas in which aberrant T cells proliferate uncontrollably. Considered as a single entity, ALCL is the most common type of peripheral lymphoma and represents ~10% of all peripheral lymphomas in children. The incidence of ALCL is estimated to be 0.25 cases per 100,000 people in the United States of America. There are four distinct types of anaplastic large-cell lymphomas that on microscopic examination share certain key histopathological features and tumor marker proteins. However, the four types have very different clinical presentations, gene abnormalities, prognoses, and/or treatments.

<span class="mw-page-title-main">History of cancer chemotherapy</span>

The era of cancer chemotherapy began in the 1940s with the first use of nitrogen mustards and folic acid antagonist drugs. The targeted therapy revolution has arrived, but many of the principles and limitations of chemotherapy discovered by the early researchers still apply.

<span class="mw-page-title-main">CHOP (chemotherapy)</span> Treatment for non-Hodgkin lymphoma

CHOP is the acronym for a chemotherapy regimen used in the treatment of non-Hodgkin lymphoma. CHOP consists of:

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

Stanford V, is a chemotherapy regimen intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:

ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs:

BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early with unfavorable risk factors. Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. There also exists a more intensive regimen with cycles of 14 days. Usually a course of BEACOPP therapy consists of four, sometimes six to eight cycles, or in combination with ABVD. In some countries BEACOPP still is experimental, in others it is a standard therapy. In the United States, ABVD is generally given instead, because BEACOPP is perceived by practicing oncologists to have the potential to induce more secondary neoplasias. However, the final results from the GHSG HD14 trial indicate that "there were no overall differences in treatment-related mortality or secondary malignancies" of BEACOPP relative to ABVD.

Panitumumab, sold under the brand name Vectibix, is a fully human monoclonal antibody specific to the epidermal growth factor receptor.

<span class="mw-page-title-main">Ipilimumab</span> Pharmaceutical drug

Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.

ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma.

<span class="mw-page-title-main">Langerhans cell sarcoma</span> Medical condition

Langerhans cell sarcoma (LCS) is a rare form of malignant histiocytosis. It should not be confused with Langerhans cell histiocytosis, which is cytologically benign. It can present most commonly in the skin and lymphatic tissue, but may also present in the lung, liver, and bone marrow. Treatment is most commonly with surgery or chemotherapy.

<span class="mw-page-title-main">Follicular dendritic cell sarcoma</span> Dendritic cell sarcoma cancer that effects the follicular dendritic cells

Follicular dendritic cell sarcoma (FDCS) is an extremely rare neoplasm. While the existence of FDC tumors was predicted by Lennert in 1978, the tumor wasn't fully recognized as its own cancer until 1986 after characterization by Monda et al. It accounts for only 0.4% of soft tissue sarcomas, but has significant recurrent and metastatic potential and is considered an intermediate grade malignancy. The major hurdle in treating FDCS has been misdiagnosis. It is a newly characterized cancer, and because of its similarities in presentation and markers to lymphoma, both Hodgkin and Non-Hodgkin subtypes, diagnosis of FDCS can be difficult. With recent advancements in cancer biology better diagnostic assays and chemotherapeutic agents have been made to more accurately diagnose and treat FDCS.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes debilitating symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is administered by slow intravenous injection.

<span class="mw-page-title-main">Durvalumab</span> Pharmaceutical drug

Durvalumab, sold under the brand name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279).

<span class="mw-page-title-main">Limited-stage small cell lung carcinoma</span> Medical condition

Limited-stage small cell lung carcinoma (LS-SCLC) is a type of small cell lung cancer (SCLC) that is confined to an area which is small enough to be encompassed within a radiation portal. This generally includes cancer to one side of the lung and those might have reached the lymph nodes on the same side of the lung. 33% patients with small cell lung cancer are diagnosed with limited-stage small cell lung carcinoma when it is first found. Common symptoms include but are not limited to persistent cough, chest pain, rust-coloured sputum, shortness of breath, fatigue, weight loss, wheezing, hoarseness and recurrent respiratory tract infections such as pneumonia and bronchitis. Nervous system problems, Cushing syndrome and SIADH can also be associated with small cell lung cancer. Unlike extensive-stage small cell lung cancer, limited-stage small cell lung carcinoma is potentially curable. Standard treatments consist of surgery, platinum-based combination chemotherapy, thoracic irradiation, and prophylactic cranial irradiation. Patient five-year survival rate has significantly increased from 1% with surgery to 26% after the application of combination chemotherapy.

<span class="mw-page-title-main">High-dose chemotherapy</span>

High-dose chemotherapy (HDC) is referring to chemotherapy medicines which are given at larger dosages than that are usually used in normal chemotherapy regimens. This therapeutic strategy is used to treat some cancers, especially those that are aggressive or have a high chance of coming back. With increased doses of chemotherapy chemicals administered to the body, HDC seeks to optimize the death of cancer cells.

References

  1. Mayer RJ (February 2009). "Targeted therapy for advanced colorectal cancer—more is not always better". N Engl J Med. 360 (6): 623–5. doi:10.1056/NEJMe0809343. PMID   19196680. letter commenting on the Clinical trial: Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ (February 2009). "Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer". N Engl J Med. 360 (6): 563–72. doi:10.1056/NEJMoa0808268. hdl: 2066/79995 . PMID   19196673.
  2. Cancer.net - Explaining Maintenance Therapy
  3. BEACOPP chemotherapy regimen
  4. "MVAC Still the 'Best Treatment' for Advanced Bladder Cancer Patients. 1999". Archived from the original on 2012-01-09. Retrieved 2010-11-18.
  5. "Ovarian Cancer Chemotherapy: Know Your Treatment Options".
  6. Rodriguez Victorio (1973). "POMP combination chemotherapy of adult acute leukemia". Cancer. 32 (1): 69–75. doi: 10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0 . PMID   4515259.
  7. Kiesewetter B, Mayerhoefer ME, Lukas J, Zielinski CC, Müllauer L, Raderer M (2014). "Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)". Ann. Hematol. 93 (2): 249–53. doi:10.1007/s00277-013-1865-3. PMID   23925930. S2CID   12851937.
  8. 1 2 3 4 5 Treatment of Wilms Tumor at National Cancer Institute. Last Modified: 03/29/2012
  9. El Weshi, A; Memon, M; Raja, M; Bazarbashi, S; Rahal, M; El Foudeh, M; Pai, C; Allam, A; El Hassan, I; Ezzat, A (October 2004). "VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors". American Journal of Clinical Oncology. 27 (5): 529–34. doi:10.1097/01.coc.0000135815.94162.83. PMID   15596925. S2CID   6362786.
  10. Kosmidis, P; Mylonakis, N; Fountzilas, G; Pavlidis, N; Samantas, E; Karabelis, A; Kattis, K; Skarlos, D (July 1996). "A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group". Annals of Oncology. 7 (5): 517–20. doi: 10.1093/oxfordjournals.annonc.a010642 . PMID   8839908.